UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its position in Sage Therapeutics, Inc. (NASDAQ:SAGE) by 12.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 72,149 shares of the biopharmaceutical company’s stock after selling 10,027 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.12% of Sage Therapeutics worth $521,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of SAGE. BNP Paribas Financial Markets increased its holdings in Sage Therapeutics by 52.2% in the third quarter. BNP Paribas Financial Markets now owns 70,986 shares of the biopharmaceutical company’s stock valued at $513,000 after buying an additional 24,356 shares during the last quarter. Dynamic Technology Lab Private Ltd boosted its position in shares of Sage Therapeutics by 100.9% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 28,549 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 14,340 shares in the last quarter. Algert Global LLC increased its holdings in shares of Sage Therapeutics by 120.6% in the 3rd quarter. Algert Global LLC now owns 143,034 shares of the biopharmaceutical company’s stock valued at $1,033,000 after acquiring an additional 78,190 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of Sage Therapeutics by 10.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 452,193 shares of the biopharmaceutical company’s stock worth $3,265,000 after acquiring an additional 43,617 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in Sage Therapeutics during the third quarter worth approximately $146,000. 99.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SAGE has been the topic of a number of research analyst reports. Stifel Nicolaus cut their price objective on shares of Sage Therapeutics from $10.00 to $6.00 and set a “hold” rating on the stock in a report on Monday, December 16th. TD Cowen cut their price target on shares of Sage Therapeutics from $10.00 to $9.00 and set a “hold” rating on the stock in a research note on Thursday, November 21st. Raymond James restated a “market perform” rating on shares of Sage Therapeutics in a research note on Thursday, October 10th. HC Wainwright reiterated a “neutral” rating and set a $14.00 target price on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Finally, Royal Bank of Canada raised Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 target price for the company in a research report on Thursday, November 21st. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, Sage Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $11.53.

Sage Therapeutics Stock Up 12.2 %

Shares of SAGE stock opened at $5.61 on Friday. The business has a fifty day simple moving average of $6.07 and a 200-day simple moving average of $8.17. Sage Therapeutics, Inc. has a fifty-two week low of $4.62 and a fifty-two week high of $28.26. The stock has a market cap of $343.18 million, a P/E ratio of -1.01 and a beta of 0.87.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.52) by ($0.01). Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The business had revenue of $11.87 million during the quarter, compared to analyst estimates of $10.80 million. During the same quarter in the prior year, the company earned ($2.81) earnings per share. The firm’s revenue for the quarter was up 337.1% compared to the same quarter last year. On average, sell-side analysts anticipate that Sage Therapeutics, Inc. will post -6.53 earnings per share for the current year.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.